Distalmotion

1. Executive Summary (Confidence: High)

Based in Lausanne, Switzerland, Distalmotion is strategically disrupting the surgical robotics market by targeting the Ambulatory Surgery Center (ASC) segment—the fastest-growing US site of care. The company raised $150 million in a Series G round in late 2025, led by Revival Healthcare Capital, and secured a strategic investment from Johnson & Johnson Innovation (JJDC) in January 2026. Its flagship product, the Dexter L6, is a compact, modular system that offers the precision of wristed robotics with the flexibility of conventional laparoscopy. To date, more than 3,000 patients have been treated with Dexter across Europe and the United States, and the system has received multiple FDA clearances for high-volume procedures including inguinal hernia repair and cholecystectomy.